====== AstraZeneca COVID-19 vaccine ======

{{ :covid-19_vaccines:gettyimages-1231888707-789886566c92abf6969dc4c47c8a44fe3f82155a-s1600-c85_copy.png?200|}}

**ChAdOx1 nCoV-19** is the name of a viral vector [[:COVID-19 vaccines|COVID-19 vaccine product]] more commonly referred to as the **Oxford-AstraZeneca** vaccine, or in colloquial terms, simply the **[[:pharmaceutical_companies:AstraZeneca]] vaccine.**

===== History =====

==== Development ====

In June 2020, the [[:Bill & Melinda Gates Foundation]] contributed $750 million to the development of the vaccine candidate.((Canellis, D. (2020, June 5). //Bill Gates commits $750M to help Oxford vaccinate the world against COVID-19.// TNW | Fintech-Ecommerce. http://archive.today/2023.02.25-123239/https://thenextweb.com/news/bill-gates-covid-coronavirus-vaccine-750-million-oxford-azd1222))

==== Distribution ====

On April 14, 2021, the [[:Danish Health Authority]] announced it would stop administering the AstraZeneca-Oxford vaccine "because of its possible link to rare cases of blood clotting" and the "fact that the COVID-19 epidemic in [[:Denmark]] is currently under control and other [[:COVID-19 vaccines|vaccines]] are available."((Treisman, R. (2021, April 14). //Denmark Drops AstraZeneca Vaccine, Citing Rare Side Effects, Epidemic “Under Control.”// NPR. http://archive.today/2021.04.21-192633/https://www.npr.org/sections/coronavirus-live-updates/2021/04/14/987166681/denmark-drops-astrazeneca-vaccine-citing-rare-side-effects-epidemic-under-contro))

On April 23, 2021, [[:Canada]]'s [[:National Advisory Committee on Immunization]] (NACI) recommended the AstraZeneca-Oxford vaccine be offered to "all Canadians over the age of 30, but only when the benefits outweigh the risks of rare, serious post-vaccine blood clots."((Pelley, L. (2021, April 23). //Canadians over 30 should be offered AstraZeneca-Oxford COVID-19 vaccine, advisory body recommends.// CBC News. http://archive.today/2021.04.24-073245/https://www.cbc.ca/news/health/astrazeneca-covid-19-vaccine-over-30-naci-1.6000052))